During the mid-90’s, when a bacterial defence system against viral invasion was being studied, few could have expected that the gene editing and targeting capabilities of machinery derived from this system could be harnessed to provide such wide-ranging practical applications; and as a result, keep our CRISPR-IP team so busy.
Having actively advised on IP matters in this field since about 2007, our understanding of the practical and commercial considerations required to develop sound IPR strategies in relation to CRISPR technologies have grown with the field itself. HGF now has one of the most experienced teams of this type in Europe.
Our core CRISPR-IP team include 5 European Patent Attorneys and a Litigation Partner.
- Dr Claire Irvine - Patent Attorney, Partner
- Dr Emma Longland - Patent Director
- Craig Thomson - Patent Attorney, Partner
- Douglas Drysdale - Patent Attorney, Partner
- Dr Richard Williams - Patent Attorney, Partner
- Rachel Fetches - IP Solicitor, Partner
This team is backed by the larger team of over 75 Patent Attorneys and Solicitors across 5 European countries, who specialise in life sciences, pharmaceuticals, chemistry and plant sciences.
With our experience, the team can advise on all aspects of patent development, from patent prosecution through to licensing, oppositions and litigation. We are engaged in opposition proceedings concerning some of the most dominant patents granted in this field in Europe. As the focus for practical applications of CRISPR technology expands, we are actively involved in advising sectors such as Human and Animal Therapeutics, Diagnostics, AgBio, Microbiome and the Plant Sciences. As we keep a close eye on the developing patent estates and ongoing disputes in this field, we are skilled at guiding users of the technology through the IP landscape to develop a robust IP strategy, including freedom to operate, licensing, opposition and litigation strategies.
For the latest key updates click here.
Follow this page for the latest updates from CRISPR BoA Hearing in Munich from Monday 13th January to Friday 17th January. HGF Patent Director Dr Emma Longland was reporting all the key moments throughout the week along with daily roundups.
As an integrated team of attorneys and solicitors we work together to advise on all aspects of IP development. Anyone wishing to know more about our CRISPR team, or the services we offer, please contact one of the Team members.
We have worked with some of the pioneers of CRISPR technology, as well as for third parties who wish to develop and expand the field. Our client base continues to develop and grow by recommendation.